Hear from a psychiatrist who saw a dozen people spiral after AI connections
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
26 minutes ago
- Yahoo
POP Launches Canine Health Study with Innovative Pet Lab and Embark to Advance Data-Driven Pet Wellness
New U.S.-based study will explore the impact of gut-focused nutrition, DNA insights, and activity tracking on canine immunity and long-term vitality HOUSTON, Aug. 14, 2025 /PRNewswire/ -- Pet wellness company POP today announced the launch of a 90-day canine health study in collaboration with Innovative Pet Lab, and Embark Veterinary. Designed to explore how personalized nutrition, biological data, and behavior tracking can support immune health and long-term vitality, the study will enroll up to 100 dogs from across the United States. Participants will receive over $600 in free health tools, including POP's science-backed supplement POP-Topper, Innovative Pet Lab's gut biomarker test kits, and Embark's DNA test. The study will also deliver a personalized health report at the end of the 90 days, combining insights from multiple data sources. "Dogs can't always tell us when something's off—but their biology and behavior can," said Alan Tsui, Co-Founder of POP. "We're combining cutting-edge diagnostics, personalized nutrition, and real-world data to give pet parents a clearer picture of their dog's health—and contribute to a future where all dogs live longer, healthier lives." POP, short for "Power of Pets," launched in 2024 to address the growing need for preventative pet health solutions rooted in science and personalization. Its flagship product, POP-Topper, is a functional food topper formulated with clinically studied ingredients that support gut health and reduce inflammation. Innovative Pet Lab will provide two at-home gut health test kits per participant to measure key markers like calprotectin, zonulin, and SIgA. Embark Veterinary, the global leader in dog DNA testing, will offer breed, trait, and genetic risk profiling to support individualized interpretation. This comprehensive study will investigate how a personalized protocol—combining diet, gut diagnostics, DNA, and behavior data—can inform smarter, more proactive dog care. Results will also contribute to future research on the early detection and prevention of chronic diseases like IBD, arthritis, and obesity. Enrollment is now open for dog owners in the U.S. with dogs aged 1–6 years. Participants must commit to feeding POP-Topper daily, submitting samples, and completing a series of surveys and weekly logs. Those who complete the study will receive a full refund of their $99 deposit. To learn more or apply, visit: About POPPOP (Power of Pets) is a next-generation pet health company dedicated to extending canine healthspan—the years dogs spend thriving, not just surviving. POP combines science-backed supplements and personalized diagnostics to help pet parents make better health decisions. Learn more at About Innovative Pet LabInnovative Pet Lab is a leader in canine gut health screening tests. Their at-home testing kits translate microbiome and immune biomarkers into actionable insights, empowering earlier intervention and improved long-term outcomes for dogs. About Embark VeterinaryEmbark offers the most comprehensive dog DNA test on the market. Developed by veterinarians and geneticists, Embark provides breed breakdowns, health risk screening, and trait insights to support proactive care. View original content to download multimedia: SOURCE POP LABS (Pet Longevity Research Limited) Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Business Wire
28 minutes ago
- Business Wire
Philips Announces Plan for More Than USD 150 Million of New Investment in Manufacturing and R&D in the U.S. to Expand Production of AI-powered Health Technology Innovations
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Philips, a global leader in health technology, today announced a plan for new investments of more than USD 150 million in U.S. manufacturing and research and development (R&D). As part of today's announcement, Philips unveiled the expansion of its Reedsville, PA, manufacturing facility, which produces AI-enabled ultrasound systems for hospitals across the U.S. These investments come on top of Philips' annual USD 900 million R&D investment in the U.S. as well as investments in nearly 17,000 colleagues across 40 facilities in the United States. Philips has employees in every U.S. state supporting innovations used by clinicians and patients in 90% of hospitals across the country. The investment announced today by Philips includes the expansion of its Reedsville, PA, site and the recently announced expansion of Philips' Image Guided Therapy facility in Plymouth, MN. It also includes additional manufacturing and R&D projects which will come over the next several years to support the company's growth in the U.S. The Reedsville site, which currently manufactures transducers, will also customize the software and configurations of ultrasound systems for specific clinical procedures in cardiovascular, general and maternal care following the expansion. As an example, Philips' industry-leading CV ultrasound platform delivers advanced tools to help doctors diagnose structural heart and coronary artery disease quickly and confidently [1]. 'The proposed planned expansion of our manufacturing facilities is a demonstration of our deep commitment to the U.S. region,' said Jeff DiLullo, Chief Region Leader, Philips North America. 'Each year, Philips spends $900 million in R&D in the U.S. to drive innovation and deliver cutting-edge technology that empowers healthcare professionals to diagnose, treat and monitor patients more effectively. Increasing our manufacturing and R&D capabilities will create jobs and accelerate our ability to deliver better care for more people with innovative AI-enabled solutions.' The expansion of the Reedsville site is expected to add 24,000 square feet of manufacturing space in addition to 40,000 square feet of warehouse space and is expected to create 120 skilled manufacturing jobs. The recently announced expansion of Philips' image-guided therapy facility in Plymouth, MN, which includes the construction of a new medtech training center, is expected to create over 150 new jobs. [1] Philips ultrasound: The next dimension in echocardiography About Royal Philips Royal Philips (NYSE: PHG, AEX: PHIA) is a leading health technology company focused on improving people's health and well-being through meaningful innovation. Philips' patient- and people-centric innovation leverages advanced technology and deep clinical and consumer insights to deliver personal health solutions for consumers and professional health solutions for healthcare providers and their patients in the hospital and the home. Headquartered in the Netherlands, the company is a leader in diagnostic imaging, ultrasound, image-guided therapy, monitoring and enterprise informatics, as well as in personal health. Philips generated 2024 sales of EUR 18 billion and employs approximately 67,300 employees with sales and services in more than 100 countries. News about Philips can be found at Forward-looking statements and other important information This release contains certain forward-looking statements with respect to the financial condition, results of operations and business of Philips and certain of the plans and objectives of Philips with respect to these items. Examples of forward-looking statements include statements made about the strategy, estimates of sales growth, future EBITA, future developments in Philips' organic business and the completion of acquisitions and divestments. By their nature, these statements involve risk and uncertainty because they relate to future events and circumstances and there are many factors that could cause actual results and developments to differ materially from those expressed or implied by these statements. This press release contains inside information within the meaning of Article 7(1) of the EU Market Abuse Regulation.
Medscape
28 minutes ago
- Medscape
FDA Panel Seeks More Data on Filler Use in Decolletage Area
A FDA advisory panel recommended that manufacturers of dermal fillers collect more information on use in the decolletage area of the body and said that some patients might be at higher risk of complications from injections because of the proximity to breast tissue. The FDA has not approved dermal fillers for use in the decolletage — a body area that advisory panel members said was not well-defined. It is generally considered the triangular area that runs from the neck and clavicle area to in between the breasts. Agency officials and committee members noted that fillers are increasingly being used off-label to improve skin texture, crepiness, skin thickness, fine lines, and wrinkles in the decolletage. The most common fillers used in the neck and decolletage are made up of hyaluronic acid (HA), calcium hydroxylapatite (CaHA), or poly-L-lactic acid (PLLA), according to the American Academy of Dermatology Association (AADA). At a meeting on August 13, the FDA's General and Plastic Surgery Devices Panel was asked to review safety concerns, in anticipation that manufacturers will soon seek FDA approval of fillers for use in the decolletage area and need guidance on trial design and post-marketing studies. The agency raised the possibility that fillers could migrate from the injection site or form nodules and/or granulomas and interfere with mammograms, cause false positive readings on breast imaging or clinical exams, or impact breast feeding and lymphatic drainage. The committee — made up of dermatologists, plastic surgeons, oncologists, and radiologists — did not formally vote. The panel members agreed that patients who are breastfeeding or pregnant should be excluded from receiving injections because of the unknowns. Individuals with darker skin types or known wound-healing issues — both of whom might easily form keloids or nodules — or those with a history of radiotherapy, lymphoma, or other blood cancers were also seen as potentially higher risk populations, said panel chairman Hobart Harris, MD, MPH, the J. Engelbert Dunphy endowed chair in surgery at the University of California, San Francisco. Sandra R. Shuffett, MD, a breast imaging specialist in Lexington, Kentucky, and temporary panel member, said she was concerned that fillers could obscure tumors on breast imaging tests. 'My focus is to find a cancer as small as possible,' she said, adding that an unseen tumor could quickly grow larger, necessitating more serious treatment. The FDA has not received reports of problems with breast feeding or imaging but a post-approval study of Radiesse (CaHA) found that it obscured bone visualization. There have also been reports of lymph node enlargement near dermal filler injection sites. FDA reviewer Sung Yoon, MD, said at the meeting that the agency is 'not aware of specific reports where breast cancer was missed' because of dermal filler but noted that off-label use might mean less reporting of adverse events. Yoon told the panel that an analysis of the FDA's Medical Device Reporting database found 20 reports of serious injury events associated with the use of dermal fillers in the decolletage area since 2007 out of 186 reports related to unapproved upper body use. It is not possible to know how many decolletage procedures have been performed, she said. The FDA reported that an estimated 6.2 million dermal filler procedures were performed in 2024. Radiesse manufacturer, Merz Aesthetics, told the panel that, between 2018 and 2025, it received 44 reports of potential adverse events in the decolletage area, with none reporting migration of material or radiological interference. Radiesse is approved for decolletage wrinkles in the European Union and Canada. Social media may be fueling more use of fillers in the decolletage, especially among those taking GLP-1 receptor agonists for weight loss who are seeking 'to improve the skin rippling in the chest,' said Karol A. Gutowski, MD, a Chicago-based plastic surgeon who spoke to the committee. Representatives from dermatology and plastic surgery organizations said they had crafted guidelines for safe use of fillers in the decolletage but warned that filler use was often unregulated. 'Filler adverse events are likely under reported, and they're increasing in frequency as the popularity of injectable fillers increases,' said M. Laurin Council, MD, director of dermatologic surgery at Washington University School of Medicine, St. Louis, who spoke to the panel on behalf of the American Society for Dermatologic Surgery. Many panelists suggested women undergo baseline breast imaging before receiving filler in the decolletage area and collecting more data — such as on the volume of filler used during procedures — and added that perhaps a registry should be created. But some were skeptical. 'Probably 75% of these injections are done by non-medical people,' such as attendants at medical spas or storefront wellness centers, said panelist Alan Matarasso, MD, a New York City-based plastic surgeon and past president of the American Society of Plastic Surgeons. Matarasso said that manufacturers should be responsible for tracking their products, not clinicians. 'When these things are being done in strip malls and other places, we're not going to get the data that we need, because people are not going to cooperate with this,' said Gutowski. There is no approved method of removing dermal fillers. That gave some panel members pause. But dermatologists and plastic surgeons said that HA-based fillers could be dissolved with hyaluronidase. Even so, CaHA and PLLA fillers can't be dissolved and 'must break down naturally over time,' said Natalie Curcio, MD, MPH, a Nashville-based dermatologist who spoke to the panel on behalf of the AADA. Temporary committee member Karla V. Ballman, PhD, professor of biostatistics at the Mayo Clinic College of Medicine and Science, Rochester, Minnesota, said that patients should be informed, perhaps via wording on a product label that 'at the current time, there is no approved method of removal' of a filler. The FDA has periodically examined dermal filler safety. In July 2023, the agency updated its informational webpage to describe a new risk of delayed-onset inflammation near treatment sites that had been reported to occur following viral or bacterial illnesses or infections, vaccinations, or dental procedures. The webpage also lists common reactions such as bruising, redness, swelling, and pain. At the panel meeting, consumer advocate Diana Zuckerman, PhD, president of the National Center for Health Research, said that listing adverse events was not enough. 'Risks should be quantified with meaningful statistical data on the short term and long term risks,' said Zuckerman, who spoke during the open public hearing. 'FDA should require well designed and full clinical trials so that patients have the information they need to make informed decisions,' she said. 'FDA really appreciates the thoughtful discussion questions and recommendations that have been provided today, and we will certainly take all of these comments into consideration as we move forward,' said Cynthia Chang, PhD, an acting division director within the agency's Center for Devices and Radiological Health.
